Study to Evaluate KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics
and initial efficacy of KD6001 in combination with toripalimab in patients with advanced
melanoma.